Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess whether therapy with Sorafenib reinduces radioiodine uptake in thyroid carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Leiden University Medical Center
• Treatments: Niacinamide; Sorafenib

Criteria

Inclusion Criteria:

• Patients with non-medullary thyroid carcinoma

• The patients must have undergone total thyroidectomy

• Presence of metastases or inoperable recurrent disease, as proven by elevated serum thyroglobulin levels (Tg) in combination with radiological evidence for tumor

• No or insufficient RaI uptake in tumor as proven by RaI scintigraphy, performed after prior RaI therapy

Exclusion Criteria:

• Pregnancy

• Other active malignancies

• Active kidney, liver or pancreatic disease or dysfunction

• Unstable angina pectoris or recent (<3 months) myocardial infarction.

• Coagulopathy